

Supplemental Table 1. Characteristics and prognostic analysis in 89 patients with pancreatic cancer

Variables	Number	MST (month)	5 year DSS Percentage (%)	univariable analysis	multivariable analysis <sup>‡</sup>	
				P Value <sup>a</sup>	HR (95%CI)	P Value <sup>b</sup>
<b>Age (years)</b>						
<65/≥65	51/38	11.1/18.6	15.1/20.2	0.1	-	-
<b>Gender</b>						
Male/Female	46/43	11.3/16.4	12.3/22.1	0.13	-	-
<b>Methylation value of HOPX-β</b>						
<1.55/≥1.55	15/74	16.4/12.1	20.0/6.7	0.4	-	-
<b>preoperative serum CA19-9</b>						
<37 U/ml/≥37 U/ml	23/66	-/10.4	53.0/4.6	<0.0001	3.31 (1.48-7.41)	0.0016
<b>Location</b>						
head	68	11.3	17.9	0.3		
body	15	29.5	16.3			
tail	6	16.33	0.0			
<b>Growth pattern</b>						
nodular/other	35/54	18.6/10.4	19.7/16.0	0.05	-	-
<b>histology</b>						
well	37	18.8	22.5	0.02	reference	0.028
moderately	34	11.1	13.5		1.57 (0.85-2.88)	
poor	18	6.5	12.5		2.74 (1.32-5.68)	
<b>tumor size (cm)</b>						
≤2	13	39.1	40.0	0.2	-	-
2<ts≤4	61	12	14.4			
4<ts≤6	13	14.8	18.2			
<6	2	11.5	0.0			
<b>ND factor</b>						
ND<10/ND10	50/39	16.4/9.5	26.3/7.2	0.01	0.94 (0.52-1.70)	0.85
<b>pancreatic cut end margin (PCM)</b>						
negative/positive	74/14	16.0/12.1	21.5/0.0	0.1	-	-
<b>bile duct cut end margin (BCM)</b>						
negative/positive	70/1	11.9/14.8	20.2/9.4	0.9	-	-
<b>dissected pancreatic tissue margin (DPM)</b>						
negative/positive	48/41	19.7/8.9	33.3/0.0	<0.0001	2.82 (1.17-6.80)	0.013
<b>residual tumor (R factor)</b>						
0	35	23.5	38.3	0.0002	reference	0.45
1	40	11.9	7.2		0.77 (0.30-1.92)	
2	14	7.1	0.0		1.16 (0.35-3.77)	
<b>stage (JPS)</b>						
III	39	23.5	28.3	<0.0001	reference	0.0085
IVa	26	12.1	19.1		2.06 (1.00-4.20)	
IVb	24	7.1	0.0		3.16 (1.48-6.73)	
<b>T factor (JPS)</b>						
1	1	-	100.0	0.006	-	-
2	3	10	0.0			
3	58	17.4	22.5			
4	27	8.9	9.2			
<b>lymph node metastasis (N) (JPS)</b>						
0	23	18.6	35.5	0.01	-	-
1	34	17	16.8			
2	19	11.1	13.4			
3	13	7.2	0.0			
<b>distant metastasis (M) (JPS)</b>						
absence/presence	82/7	16.3/7.0	18.6/0.0	0.0003	-	-
<b>stage (UICC)</b>						
IB	1	-	100.0	<0.0001	-	-
IIA	21	18.6	33.6			
IIB	46	17.3	17.8			
III	3	3.6	0.0			
IV	18	7.2	0.0			
<b>T factor (UICC)</b>						
1	3	26.5	0.0	<0.0001	-	-
2	7	18.2	28.6			
3	78	14.8	17.0			
4	1	2.2	0.0			
<b>lymph node metastasis (N) (UICC)</b>						
0/1	23/66	18.6/11.3	35.5/12.2	0.02	-	-
<b>distant metastasis (M) (UICC)</b>						
absence/presence	71/18	17.3/7.2	22.1/0.0	<0.0001	-	-
<b>operation</b>						
PD	67	11.3	18.7	0.3	-	-
DP	20	18.8	11.1			
TP	2	-	100.0			
<b>lymph node dissection (D)</b>						
0,1	11	18.4	55.5	0.3	-	-
2	32	16.3	25.3			
2+α	40	11.1	17.0			
3	6	9.5	0.0			
<b>post operative therapy (including adjuvant therapy)</b>						
absence/presence	32/57	11.9/16.4	8.4/20.9	0.1	-	-
<b>Methylation value of HOPX-β</b>						
<3.6/≥3.6	23/66	16.4/12.1	19.2/9.6	0.9	-	-

Abbreviations: DSS disease-specific survival; MST median survival time; HR hazard ratio; CI confidence interval

<sup>a</sup> log-rank test<sup>b</sup> significant based on Cox's proportional hazard model<sup>‡</sup> Multivariable analysis was indicated excluding constructing factors of JPS staging system, and UICC staging system was not adopted due to divide.